What are the long‑term outcomes and patient satisfaction rates for combined VED plus daily PDE5i therapy?
Executive summary
Combining a vacuum erection device (VED) with daily phosphodiesterase‑5 inhibitor (PDE5i) therapy is repeatedly reported to improve erectile metrics and rescue men who failed PDE5i monotherapy, with several series showing meaningful increases in International Index of Erectile Function (IIEF) scores and intercourse success; however, the literature is heterogeneous, short‑to‑medium term, and patient satisfaction rates are mixed depending on the population and comparator [1] [2] [3]. Guideline panels recognize VEDs as an option and endorse shared decision‑making because evidence quality and long‑term adherence data are limited [4] [5].
1. Compelling but varied signals of improved erectile function
Multiple prospective and retrospective cohorts report that adding VED to PDE5i leads to objective and patient‑reported improvements in erectile function: one review cites a prospective study in which VED plus PDE5i roughly doubled IIEF scores and others showing improvement in 71% of patients offered combination approaches after failed monotherapy [2] [1]. Case series aggregated in systematic reviews describe gains across IIEF domains—erectile function, intercourse satisfaction, orgasmic function, sexual desire and overall satisfaction—often in men who had inadequate responses to PDE5i alone [1].
2. Patient satisfaction: often better than failure but not uniformly superior to monotherapy
When men who failed PDE5i were offered VED plus PDE5i, the majority improved on measures like perceived rigidity, partner and patient satisfaction and successful penetration rates (77% in one series) [1]. At the same time, comparative signals are mixed: some cohort data in broader combination‑therapy reviews suggest PDE5i monotherapy scored higher for convenience and satisfaction than certain drug combinations, and a retrospective cohort found greater satisfaction with PDE5i alone versus PDE5i plus prostaglandin E1 (PG‑E1) [2]. General baseline figures for PDE5i response and satisfaction—first‑time response ~60–70% and high reported long‑term success when multiple agents tried—frame the context in which combination therapy is usually deployed for partial or non‑responders [3] [6].
3. Short follow‑up, small series, and selection bias limit “long‑term” claims
Most positive data derive from small prospective studies, case series, and retrospective cohorts with follow‑up typically measured in weeks to months; systematic summaries explicitly grade the evidence as level 2–4 rather than high‑quality randomized long‑term trials [1] [2]. Guideline statements therefore recommend discussing VEDs as an option but stop short of robust long‑term endorsements because placebo effects, psychosocial factors, and the variable natural history of ED complicate attribution of sustained benefit [4] [5].
4. Who benefits and why: patient selection and hidden agendas
The clearest signal of benefit is in men who are PDE5i partial‑responders or non‑responders—combination therapy is frequently studied as a “rescue” strategy rather than first‑line treatment, and industry and specialty review articles sometimes emphasize multimodal options that can delay or avoid invasive therapies [2] [7]. That framing can create an implicit agenda to promote stepwise escalation; conversely, patient‑preference literature warns that convenience, spontaneity and side‑effect profiles strongly influence long‑term adherence, which may favor simpler regimens for some men [8] [9].
5. Practical bottom line for clinicians and patients
For men failing PDE5i alone, adding a VED to daily PDE5i has reasonable evidence of improving erectile outcomes and sexual satisfaction in the short‑to‑medium term and is recommended as an option in practice guidelines; nevertheless, long‑term outcome and adherence data are sparse and satisfaction is not universally superior to monotherapy across all comparisons, so shared decision‑making that weighs convenience, partner preferences and likelihood of adherence is essential [1] [4] [2]. Future randomized long‑term trials and standardized satisfaction measures are needed to resolve remaining uncertainty about durability and real‑world patient preference [2] [1].